7 recruiting, 3 completed, 3 unknown, 2 active not recruiting. 7 Phase 4, 3 Phase 3, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Recruiting 3, Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Unknown 2 |
| Not applicable | 1 | Recruiting 1 |
Follow Viatris Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD) Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline) - COPD Exacerbation | Phase 4 | Not yet recruiting | University of Tennessee Graduate School of Medicine | 280 | 2026-11-12 | 2026-10-19 |
| Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill - Talaromycosis | Phase 3 | Not yet recruiting | Duke University | 428 | 2026-11-01 | 2026-09-21 |
| Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR) Bedaquiline Oral Tablet - MDR-TB, Tuberculosis Multi Drug Resistant Active | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 55 | 2026-09-11 | 2026-09-16 |
| Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users Placebo, Oxycodone 20mg, gabapentin 600 mg - Healthy | Phase 4 | Recruiting | Viatris Inc. | 60 | 2026-08-03 | 2026-10-15 |
| Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg Tyrvaya - Dry Eye | Not applicable | Recruiting | Ocular Aesthetics, LLC dba Ocular Clinical Trials | 50 | 2026-07-28 | 2026-07-30 |
| Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience Alprazolam (Xanax), Placebo, Gabapentin (Neurontin® (Registered Trademark)) - Healthy Non-dependent, Recreational Sedative Users | Phase 4 | Completed | Viatris Inc. | 44 | 2026-06-18 | 2026-09-08 |
| Dymista in Chinese Adolescents Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate - Allergic Rhinitis Due to Allergens | Phase 4 | Active not recruiting | Viatris Inc. | 100 | 2026-05-08 | 2026-09-29 |
| Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment Varenicline 0.03Mg/Spray Nasal Soln - Dry Eye, Meibomian Gland Dysfunction | Phase 4 | Recruiting | University of California, Berkeley | 65 | 2026-03-06 | 2026-05-27 |
| Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced CONstipation: Clinical Outcomes and Patient Experience Naldemedine, an peripherally acting opioid antagonist - Cancer, Opioid Induced Constipation (OIC) | Recruiting | Professor Monique A. H. Steegers | 100 | 2026-01-02 | 2026-01-02 | |
| Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo - Mesopic Vision, Night Vision Loss | Phase 3 | Completed | Opus Genetics, Inc | 200 | 2024-04-01 | 2026-10-26 |
| A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions Sacubitril and Valsartan Tablets 49mg/51mg, Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg) - Bioequivalence Study | Phase 1 | Unknown | Viatris Inc. | 48 | 2024-04-01 | 2024-02-22 |
| A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions Sacubitril and Valsartan Tablets 97mg/103mg, Entresto (Sacubitril and Valsartan Tablets 97mg/103mg) - Chronic Heart Failure | Phase 1 | Unknown | Viatris Inc. | 48 | 2024-03-01 | 2024-02-20 |
| PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II) Sildenafil, Erectile vacuum device - Erectile Dysfunction Following Radical Prostatectomy | Phase 4 | Recruiting | The Netherlands Cancer Institute | 198 | 2024-01-15 | 2025-03-13 |
| Impairments That Affect Correct Inhaler Use in COPD COPD | Active not recruiting | COPD Foundation | 500 | 2023-12-14 | 2025-05-11 | |
| Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance Dovprela - Dovprela | Unknown | Viatris Inc. | 100 | 2023-07-23 | 2024-06-24 | |
| Phase 4 COPD and Suboptimal Inspiratory Flow Rate Revefenacin, Tiotropium, Revefenacin Placebo - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Theravance Biopharma | 404 | 2022-01-07 | 2024-12-20 |
| PsoBest - The German Psoriasis Registry Psoriasis, Psoriatic-arthritis | Recruiting | Universitätsklinikum Hamburg-Eppendorf | 3500 | 2008-01-01 | 2026-10-27 |
Dry Eye Syndromes (2) · Pulmonary Disease, Chronic Obstructive (2) · Arthritis, Psoriatic (1) · Lacerations (1) · Meibomian Gland Dysfunction (1) · Neoplasms (1) · Opioid-Induced Constipation (1) · Psoriasis (1) · Rhinitis, Allergic (1) · Tuberculosis (1) · Tuberculosis, Multidrug-Resistant (1) · Vitamin A Deficiency (1) · talaromycosis (1)
Gabapentin (2) · Valsartan (2) · revefenacin (2) · sacubitril (2) · sacubitril and valsartan sodium hydrate drug combination (2) · Albuterol (1) · Alprazolam (1) · Flucytosine (1) · Fluticasone (1) · Formoterol Fumarate (1) · Ipratropium (1) · Oxycodone (1) · Sildenafil Citrate (1) · Therapeutics (1) · Tiotropium Bromide (1)
United States (9) · Netherlands (2) · China (1) · France (1) · Germany (1) · South Korea (1) · Thailand (1) · Vietnam (1)
Ariya Khunvichai, Ph.D (2) · Donald A Mahler, MD (1) · Duc Tung Nguyen, Dr. (1) · Inge Cox, MD (1) · Matthias Augustin, Prof. Dr. (1) · Melianthe Nicolai, MD/PhD (1) · Thuy Le, MD, PhD (1)